JACOBIO-B (JACOBIO Pharmaceuticals Group Co., Ltd.) disclosed that it bought back 63,900 ordinary shares on 21 April 2026 via the Hong Kong Stock Exchange at prices between HKD 7.79 and HKD 7.80 per share, spending approximately HKD 0.50 million.

Following the transaction, issued shares excluding treasury stock fell to 785.61 million, while treasury shares increased to 6.15 million. Total issued shares remained unchanged at 791.76 million.

The purchase forms part of a mandate approved on 10 June 2025 authorizing the company to repurchase up to 78.87 million shares. To date, 3.13 million shares have been bought back under this mandate, representing 0.40 % of the share count at the time of approval, leaving capacity for a further 75.74 million shares.

Under Hong Kong listing rules, JACOBIO-B is restricted from issuing new shares or disposing of treasury shares until 21 May 2026.